Xarelto FDA Approved Drugs
XARELTO [RivaroxabanC19H18ClN3O5S]
RX
- 10mg (oral tablet)
15mg (oral tablet)
20mg (oral tablet)
Janssen PharmsJul 1, 2011
- Following initial 6 months treatment for deep vein thrombosis (dvt) and/or pulmonary embolism (pe), reduction in the risk of recurrence of dvt and of pe with once daily, rapid-release tablet administered for at least five consecutive days.
- Prophylaxis of deep vein thrombosis (dvt).
- Prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism in patients undergoing knee or hip replacement surgery, with once daily, rapid-release tablet administered for at least five consecutive days.
- Reduce the risk of stroke in patients with nonvalvular atrial fibrillation with once daily, rapid-release tablet administered for at least five consecutive days.
- Reducing the risk of stroke and systemic embolism.
- Reduction in the risk of recurrence of deep vein thrombosis (dvt) and pulmonary embolism.
- Treatment of deep vein thrombosis (dvt).
- Treatment of deep vein thrombosis with once daily, rapid-release tablet administered for at least five consecutive days.
- Treatment of pulmonary embolism (pe).
- Treatment of pulmonary embolism with once daily, rapid-release tablet administered for at least five consecutive days.
WARNING: Consult a licensed physician in the appropriate field for medical treatment and drug prescription. Do not self medicate.